Empowered Funds LLC Acquires New Position in Ralliant Corporation $RAL

Key Points

• Empowered Funds LLC acquired 112,205 Ralliant shares worth approximately $8.26 million, while several major institutions—including BlackRock, Viking Global Investors and State Street—also initiated positions during the second quarter.
• Ralliant insiders sold shares under pre-arranged Rule 10b5-1 plans: CEO Tamara Newcombe sold about $928,675 worth and SVP Karen Bick sold $436,464 worth. Corporate insiders now own 0.42% of the company.
• Ralliant exceeded quarterly earnings expectations with EPS of $0.68 versus the $0.63 consensus and issued FY 2026 EPS guidance of $2.76–$2.90. Analysts maintain a “Moderate Buy” consensus with a $75.70 average price target, while the company announced a quarterly dividend of $0.05 per share.

Empowered Funds LLC bought a new position in shares of Ralliant Corporation (NYSE:RAL - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 112,205 shares of the company's stock, valued at approximately $8,262,000. Empowered Funds LLC owned 0.10% of Ralliant as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Ralliant in the second quarter valued at $1,039,481,000. Viking Global Investors LP purchased a new stake in Ralliant during the 2nd quarter worth about $257,200,000. State Street Corp acquired a new stake in Ralliant in the 2nd quarter valued at about $213,096,000. Millennium Management LLC raised its position in Ralliant by 172.4% in the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company's stock valued at $253,175,000 after purchasing an additional 3,147,660 shares in the last quarter. Finally, Flossbach Von Storch SE purchased a new position in shares of Ralliant in the 2nd quarter valued at about $222,460,000.

Insider Activity

In other Ralliant news, CEO Tamara S. Newcombe sold 12,936 shares of the company's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $71.79, for a total transaction of $928,675.44. Following the completion of the sale, the chief executive officer directly owned 251,967 shares of the company's stock, valued at $18,088,710.93. This represents a 4.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karen M. Bick sold 6,062 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $72.00, for a total value of $436,464.00. Following the sale, the senior vice president directly owned 31,668 shares of the company's stock, valued at $2,280,096. The trade was a 16.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.42% of the stock is currently owned by corporate insiders.

Ralliant Price Performance

Shares of NYSE RAL opened at $61.65 on Friday. The company has a current ratio of 1.52, a quick ratio of 1.00 and a debt-to-equity ratio of 0.75. The stock has a market cap of $6.82 billion, a P/E ratio of -5.68, a P/E/G ratio of 2.29 and a beta of 1.60. The stock has a 50 day moving average of $68.40 and a two-hundred day moving average of $56.42. Ralliant Corporation has a twelve month low of $37.27 and a twelve month high of $75.41.

Ralliant (NYSE:RAL - Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported $0.68 EPS for the quarter, beating analysts' consensus estimates of $0.63 by $0.05. The business had revenue of $567.80 million for the quarter. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, research analysts forecast that Ralliant Corporation will post 2.87 earnings per share for the current year.

Ralliant Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 8th. Ralliant's dividend payout ratio is presently -1.84%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Evercore assumed coverage on Ralliant in a research report on Tuesday, June 9th. They set an "outperform" rating and a $80.00 price objective for the company. Weiss Ratings reiterated a "sell (d)" rating on shares of Ralliant in a research note on Friday, July 31st. Royal Bank Of Canada boosted their price target on shares of Ralliant from $71.00 to $73.00 and gave the stock a "sector perform" rating in a report on Friday, July 31st. Oppenheimer increased their price objective on shares of Ralliant from $50.00 to $65.00 and gave the company an "outperform" rating in a research report on Wednesday, May 13th. Finally, Barclays raised their price objective on shares of Ralliant from $52.00 to $67.00 and gave the company an "overweight" rating in a report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Ralliant has an average rating of "Moderate Buy" and a consensus price target of $75.70.

About Ralliant

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source